24-GU-86-FP (ABLE-32): A Phase 3b, Randomised, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC)

Grants and Contracts Details

StatusActive
Effective start/end date3/4/25 → 3/4/27

Funding

  • Ferring Pharmaceuticals AS: $2.00